Log In
Print this Print this

FP 1097

  Manage Alerts
Collapse Summary General Information
Company FemmePharma Inc.
DescriptionIntravaginal formulation of oxybutynin, a competitive antagonist of the M1, M2 and M3 subtypes of the muscarinic acetylcholine receptor
Molecular Target Muscarinic acetylcholine receptor M1 (CHRM1) (HM1) ; Muscarinic acetylcholine receptor M2 (CHRM2) (HM2)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationIncontinence
Indication DetailsTreat urinary incontinence or overactive bladder (OAB)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today